{{Chembox
| Verifiedfields = changed
| verifiedrevid = 444391072
| ImageFile = Selexipag.svg
| ImageSize = 250px
| IUPACName = 2-{4-[(5,6-diphenylpyrazin-2-yl)(propan-2-yl)amino]butoxy}-''N''-(methanesulfonyl)acetamide
| OtherNames = ACT-293987, NS-304
|Section1={{Chembox Identifiers
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = P7T269PR6S
| IUPHAR_ligand = 7552
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 8089417
| InChI = 1/C26H32N4O4S/c1-20(2)30(16-10-11-17-34-19-24(31)29-35(3,32)33)23-18-27-25(21-12-6-4-7-13-21)26(28-23)22-14-8-5-9-15-22/h4-9,12-15,18,20H,10-11,16-17,19H2,1-3H3,(H,29,31)
| InChIKey = QXWZQTURMXZVHJ-UHFFFAOYAA
| StdInChI = 1S/C26H32N4O4S/c1-20(2)30(16-10-11-17-34-19-24(31)29-35(3,32)33)23-18-27-25(21-12-6-4-7-13-21)26(28-23)22-14-8-5-9-15-22/h4-9,12-15,18,20H,10-11,16-17,19H2,1-3H3,(H,29,31)
| StdInChIKey = QXWZQTURMXZVHJ-UHFFFAOYSA-N
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| CASNo_Ref = {{cascite|correct|??}}
| CASNo = 475086-01-2
| PubChem = 9913767
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 238804
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D09994
| ChEBI_Ref = {{ebicite|correct|EBI}} 
| ChEBI = 90844
| SMILES = CC(C)N(CCCCOCC(=O)NS(=O)(=O)C)C1=CN=C(C(=N1)C2=CC=CC=C2)C3=CC=CC=C3
 }}
|Section2={{Chembox Properties
| Formula = C<sub>26</sub>H<sub>32</sub>N<sub>4</sub>O<sub>4</sub>S
| MolarMass = 496.6 g·mol<sup>−1</sup>
| Appearance = 
| Density = 
| MeltingPt = 
| BoilingPt = 
| Solubility = 
 }}
|Section3={{Chembox Hazards
| MainHazards = 
| FlashPt = 
| AutoignitionPt = 
 }}
|Section6={{Chembox Pharmacology
| ATCCode_prefix = B01
| ATCCode_suffix = AC27
 }}
}}

'''Selexipag''' (brand name '''Uptravi''') is a drug developed by [[Actelion]] for the treatment of [[pulmonary arterial hypertension]] (PAH). Selexipag and its [[active metabolite]], [[ACT-333679]] (or MRE-269, the free [[carboxylic acid]]), are [[agonist]]s of the [[prostacyclin receptor]], which leads to [[vasodilation]] in the pulmonary circulation.<ref>{{Cite journal 
| last1 = Sitbon | first1 = O. 
| last2 = Morrell | first2 = N. 
| doi = 10.1183/09059180.00004812 
| title = Pathways in pulmonary arterial hypertension: The future is here 
| journal = European Respiratory Review 
| volume = 21 
| issue = 126 
| pages = 321–327 
| year = 2012 
| pmid = 23204120 
| pmc = 
}}</ref>

[[File:MRE 269 skeletal.svg|thumb|left|ACT-333679 or MRE-269, the active metabolite of selexipag]]
{{clear left}}

==Contraindications==
In Europe, use of selexipag together with strong inhibitors of the liver enzyme [[CYP2C8]], such as [[gemfibrozil]], is contraindicated because it increases concentrations of selexipag twofold, and its active metabolite 11-fold, potentially leading to more adverse effects.<ref>{{citation|title=Information des Bundesamtes für Sicherheit im Gesundheitswesen zu Uptravi|publisher=Österreichisches Bundesamt für Sicherheit im Gesundheitswesen|language=de|date=2017-06-07}}</ref>

==History==
The [[US FDA]] granted selexipag [[Orphan Drug]] status for PAH.<ref name=FDA-apn/> It was approved by the US FDA on 22 December 2015.<ref name=FDA-apn>[http://www.pharmacypracticenews.com/ViewArticle.aspx?ses=ogst&d=Clinical&d_id=50&i=December+2015&i_id=1273 New Drug Approved for Rare Lung Disorder. PPN. 23 Dec 2015] Has link to GRIPHON study results</ref> The expected price for the drug in the US is $160,000 to $170,000 per patient before [[rebate (marketing)|rebate]]s.<ref>{{Cite news|title = Actelion sees Uptravi price of $160,000-170,000/patient|url = https://www.reuters.com/article/us-actelion-pah-prices-idUSKBN0UJ1SQ20160105|newspaper = Reuters|date = 2016-01-05|access-date = 2016-01-06}}</ref>

In Europe, the drug was approved in May 2016.<ref>{{cite web|url=http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/003774/human_med_001970.jsp&mid=WC0b01ac058001d124|title=Uptravi: Authorisation details|publisher=[[European Medicines Agency]]|date=2016-05-12}}</ref>

==See also==
* [[Epoprostenol]], another name for prostacyclin
* Analogues of prostacyclin:
** [[Beraprost]]
** [[Iloprost]]
** [[Treprostinil]]

==References==
<references/>

{{PAH rx}}
{{Prostanoidergics}}

[[Category:Acetamides]]
[[Category:Drugs acting on the cardiovascular system]]
[[Category:Pyrazines]]
[[Category:Sulfonamides]]


{{cardiovascular-drug-stub}}